Marilena Vrana Joins ARMONIA 2025 in Athens to Discuss Plasma Access
Marilena Vrana, Vice President at the Plasma Protein Therapeutics Association (PPTA) Europe, shared on LinkedIn:
”Why does the dependency of Europe on the US for plasma for fractionation persist? What does it mean for patient access and health-systems resilience?
These are some of the questions we will explore at ARMONIA’s 1st Conference on Primary Immunodeficiencies on 12 November in Athens, where I will represent PPTA Europe, Plasma Protein Therapeutics Association (PPTA).
Plasma and plasma-derived therapies availability is a public-health issue with very real consequences for people whose lives depend on them. I look forward to a forward-looking, evidence-based discussion with all stakeholders present.
CU in Athens.
12 November 2025
Wyndham Grand Athens
Agenda here.”
Keep up with Hemostasis Today.
-
Mar 12, 2026, 20:44Honoring Marion Stolte’s Lasting Impact on the Bleeding Disorders Community – WFH
-
Mar 12, 2026, 20:37Paul Riley: Is Thrombin Generation Assay Ready for Prime Time?
-
Mar 12, 2026, 20:28Rob Maloney: Building Visibility for Bleeding Disorders in Rural Georgia
-
Mar 12, 2026, 20:19Akshat Jain: Validating Oral Pain Medication Use as a Global Marker in Sickle Cell Disease
-
Mar 12, 2026, 20:13Michael Makris: Early Clinical Results of AAV8-BDD FVIII Gene Therapy in Hemophilia A
-
Mar 12, 2026, 20:02Wolfgang Miesbach: From Heparin to Vaccines – The Expanding Biology of Anti-PF4 Immunothrombosis
-
Mar 12, 2026, 19:56Christophe Dubois: Celebrating Nicolas Gendron’s HDR Defense and Future in Hemostasis
-
Mar 12, 2026, 17:06Caitlin Raymond: Managing Crigler–Najjar Syndrome Type 1 Crisis Without a Standard TPE Protocol
-
Mar 12, 2026, 17:03Jan Sloves: Insights on Comprehensive Venous Duplex Imaging at VEITH Symposium 2025